Company intelligence / Profile preview

Accuronix Therapeutics

Saint Louis, Missouri, United Statesseed.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

ACXT-3102, their lead candidate, has shown 35-fold increased cytotoxicity against pancreatic tumor cells in vitro compared to dm-erastin alone. The company is preparing for IND submission and has completed manufacturing of 1 kilogram of the compound to support ongoing preclinical development.

Therapeutic areas: Oncology
Modalities: Small molecule drug conjugates
Industry: Biotech

Drug pipeline

1 asset

ACXT-3102

Preclinical

Partnerships

Washington University School of Medicine in St. Louis (WUSM)

Beyond the preview

Go deeper on Accuronix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accuronix Therapeutics.

Explore the full profile